Tag Archives: La Jolla Pharmaceutical Co.

European drug regulator comes out of hibernation in new Dutch headquarters, rivaling the FDA with rulings; well, just for one week.

It may have taken nearly 6 months and perhaps a Fourth of July holiday-shortened work week here in the US, but the European Medicines Agency (EMA) finally issued some new… Read more »

Medical Stock Spotlight: Three winners from last week hit with profit-taking, while one big loser rebounds. This week, Provention shines, but Cymabay bombs.

Stocks continue to be whipsawed by sudden upward, then plunging, prices, only to reverse direction again as political and economic uncertainty reigns supreme. Here are four prime examples of this… Read more »

Spotlight on three winning stocks from the past week and one absolute washout. But buy the dud first, then see what we think about the others.

1) Axsome Therapeutics Inc. (Nasdaq:AXSM) led advancing issues, skyrocketing 180% last week to $7.36. On Jan. 7, the NYC-based company reported that its lead drug candidate, AXS-05, hit its primary endpoint in… Read more »